The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents ...

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality ...

Yet oncology products have a greater likelihood than other therapy areas to fail at Phase III (see graph) – well after the branding process has already begun and market expectations are somewhat ...

Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 ...

Joe DePinto, MBA, discussed the findings of the McKesson 2024 Cell and Gene Therapy Report, providing insight into the ...

At the same time, the expiration of key patents is coming up for some major Pfizer drugs, including blood thinner Eliquis and ...

Early in 2024, we reported on the FDA's call for new boxed warnings on the labeling of all approved chimeric antigen receptor ...

The latest advances in cancer therapy, coupled with the drive to bring new drugs to market via accelerated access programmes, means market researchers must keep pace to support optimum positioning.

Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

Verastem Oncology said its treatment for recurrent low-grade serous ovarian cancer has been given priority review by the Food and Drug Administration. The new drug application for the treatment in ...